aTyr Pharma, Inc. (LIFE) Earns Overweight Rating from Analysts at Piper Jaffray Companies
Piper Jaffray Companies assumed coverage on shares of aTyr Pharma, Inc. (NASDAQ:LIFE) in a research note published on Thursday, Marketbeat Ratings reports. The firm issued an overweight rating and a $7.00 price target on the biotechnology company’s stock.
LIFE has been the subject of several other research reports. Zacks Investment Research cut aTyr Pharma from a buy rating to a hold rating in a research report on Saturday, August 19th. BMO Capital Markets set a $4.00 price objective on aTyr Pharma and gave the stock a hold rating in a research report on Tuesday, August 15th. Finally, ValuEngine cut aTyr Pharma from a sell rating to a strong sell rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The company has an average rating of Hold and an average target price of $4.27.
aTyr Pharma (NASDAQ LIFE) traded up 3.28% during midday trading on Thursday, reaching $3.15. The company’s stock had a trading volume of 94,347 shares. The firm’s market capitalization is $75.09 million. aTyr Pharma has a 52 week low of $2.10 and a 52 week high of $4.45. The stock has a 50 day moving average of $3.04 and a 200 day moving average of $3.31.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.06. On average, equities research analysts predict that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.
WARNING: “aTyr Pharma, Inc. (LIFE) Earns Overweight Rating from Analysts at Piper Jaffray Companies” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/10/atyr-pharma-inc-life-earns-overweight-rating-from-analysts-at-piper-jaffray-companies.html.
In other aTyr Pharma news, CEO John Mendlein acquired 37,736 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average price of $2.65 per share, with a total value of $100,000.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Paul Schimmel acquired 94,336 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were acquired at an average cost of $2.65 per share, with a total value of $249,990.40. Following the transaction, the director now directly owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by insiders.
A hedge fund recently raised its stake in aTyr Pharma stock. EcoR1 Capital LLC raised its position in aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,292,659 shares of the biotechnology company’s stock after acquiring an additional 1,315,673 shares during the period. aTyr Pharma comprises approximately 2.0% of EcoR1 Capital LLC’s holdings, making the stock its 13th largest holding. EcoR1 Capital LLC owned 9.65% of aTyr Pharma worth $8,024,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 46.66% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.